Dexasone
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
National Cancer Institute (NCI)Small moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
33 Active assets in the High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rituximab Yazeed Sawalha | Phase 2 | B |
Cyclophosphamide Mayo Clinic | Phase 2 | B |
Etoposide David Bond, MD | Phase 2 | B |
Ibrutinib National Cancer Institute (NCI) | Phase 2 | B |
Venetoclax National Cancer Institute (NCI) | Phase 2 | B |
View all 40 →
Same molecule, other indications
Dexasone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →